288 related articles for article (PubMed ID: 24835462)
21. Eliglustat: A Review in Gaucher Disease Type 1.
Scott LJ
Drugs; 2015 Sep; 75(14):1669-78. PubMed ID: 26384672
[TBL] [Abstract][Full Text] [Related]
22. Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.
Bennett LL; Turcotte K
Drug Des Devel Ther; 2015; 9():4639-47. PubMed ID: 26345314
[TBL] [Abstract][Full Text] [Related]
23. Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease.
Giraldo P; Latre P; Alfonso P; Acedo A; Alonso D; Barez A; Corrales A; Franco R; Roldan V; Serrano S; Pocovi M
Haematologica; 2006 May; 91(5):703-6. PubMed ID: 16627252
[TBL] [Abstract][Full Text] [Related]
24. Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1.
Cox TM; Charrow J; Lukina E; Mistry PK; Foster MC; Peterschmitt MJ
Genet Med; 2023 Feb; 25(2):100329. PubMed ID: 36469032
[TBL] [Abstract][Full Text] [Related]
25. Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up.
Elstein D; Haims AH; Zahrieh D; Cohn GM; Zimran A
Blood Cells Mol Dis; 2014; 53(1-2):56-60. PubMed ID: 24581483
[TBL] [Abstract][Full Text] [Related]
26. A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and duration.
Peterschmitt MJ; Cox GF; Ibrahim J; MacDougall J; Underhill LH; Patel P; Gaemers SJM
Blood Cells Mol Dis; 2018 Feb; 68():185-191. PubMed ID: 28126395
[TBL] [Abstract][Full Text] [Related]
27. Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy.
Kim YM; Shin DH; Park SB; Cheon CK; Yoo HW
BMC Med Genet; 2017 May; 18(1):55. PubMed ID: 28506293
[TBL] [Abstract][Full Text] [Related]
28. Gaucher disease and its treatment options.
Bennett LL; Mohan D
Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
[TBL] [Abstract][Full Text] [Related]
29. Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study.
Boomsma JM; van Dussen L; Wiersma MG; Groener JE; Aerts JM; Maas M; Hollak CE
Blood Cells Mol Dis; 2010 Mar; 44(3):181-7. PubMed ID: 20074983
[TBL] [Abstract][Full Text] [Related]
30. Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1.
Peterschmitt MJ; Freisens S; Underhill LH; Foster MC; Lewis G; Gaemers SJM
Orphanet J Rare Dis; 2019 Jun; 14(1):128. PubMed ID: 31174576
[TBL] [Abstract][Full Text] [Related]
31. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.
Elstein D; Hollak C; Aerts JM; van Weely S; Maas M; Cox TM; Lachmann RH; Hrebicek M; Platt FM; Butters TD; Dwek RA; Zimran A
J Inherit Metab Dis; 2004; 27(6):757-66. PubMed ID: 15505381
[TBL] [Abstract][Full Text] [Related]
32. Plasma chitotriosidase activity versus CCL18 level for assessing type I Gaucher disease severity: protocol for a systematic review with meta-analysis of individual participant data.
Raskovalova T; Deegan PB; Yang R; Pavlova E; Stirnemann J; Labarère J; Zimran A; Mistry PK; Berger M
Syst Rev; 2017 Apr; 6(1):87. PubMed ID: 28427477
[TBL] [Abstract][Full Text] [Related]
33. Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients.
Poll LW; Koch JA; Willers R; Aerts H; Scherer A; Häussinger D; Mödder U; vom Dahl S
Blood Cells Mol Dis; 2002; 28(2):209-20. PubMed ID: 12064917
[TBL] [Abstract][Full Text] [Related]
34. Plasma glucosylsphingosine correlations with baseline disease burden and response to eliglustat in two clinical trials of previously untreated adults with Gaucher disease type 1.
Peterschmitt MJ; Foster MC; Ji AJ; Zajdel MB; Cox GF
Mol Genet Metab; 2023 Mar; 138(3):107527. PubMed ID: 36739645
[TBL] [Abstract][Full Text] [Related]
35. Eliglustat: first global approval.
Poole RM
Drugs; 2014 Oct; 74(15):1829-36. PubMed ID: 25239269
[TBL] [Abstract][Full Text] [Related]
36. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
Gonzalez DE; Turkia HB; Lukina EA; Kisinovsky I; Dridi MF; Elstein D; Zahrieh D; Crombez E; Bhirangi K; Barton NW; Zimran A
Am J Hematol; 2013 Mar; 88(3):166-71. PubMed ID: 23386328
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease.
Zimran A; Gonzalez-Rodriguez DE; Abrahamov A; Elstein D; Paz A; Brill-Almon E; Chertkoff R
Blood Cells Mol Dis; 2015 Jan; 54(1):9-16. PubMed ID: 25453586
[TBL] [Abstract][Full Text] [Related]
38. Type 1 Gaucher disease (CYP2D6-eliglustat).
Becquemont L
Therapie; 2017 Apr; 72(2):323-326. PubMed ID: 28242126
[TBL] [Abstract][Full Text] [Related]
39. Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease.
Erikson A; Forsberg H; Nilsson M; Aström M; Månsson JE
Acta Paediatr; 2006 Mar; 95(3):312-7. PubMed ID: 16497642
[TBL] [Abstract][Full Text] [Related]
40. Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy.
Zimran A; Goldblatt J; Szer J
Blood Cells Mol Dis; 2018 Feb; 68():14-16. PubMed ID: 28935503
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
